Drug Trial Radar · NCT07357220
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Feb 28, 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- Collaborators
- Shanghai Virogin Biotech Co., Ltd.
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.
Conditions
- Colorectal Cancer With Hepatic Metastases
Interventions
VG2025Biological
Recommended Phase II Dose, Intratumoral Injection, Q4W
AK112Drug
20mg/kg, ivgtt, Q2W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants experiencing dose-limiting toxicities (DLTs)Time frame: From Day 1 to Day 28 after the first tumour vaccine was administrated in safety run-in cohorts
- Number of participants with adverse events (AEs) and severityTime frame: From ICF up to 30 days after last study treatment
- Objective Response Rate (ORR)Time frame: Time Frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, Zhejiang University School of Medicine,No. 79, Qingchun Road, Shangcheng District, Hangzhou City, Zhejiang Province
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.